Key statistics dashboard for Zai Lab Limited (ZLAB). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders.
Stock Data
| Price | $24.67 |
| Market Cap | $2.8B |
| Enterprise Value | $2.44B |
| Beta | 0.86 |
| Exchange | NASDAQ |
| Country | CN |
Valuation Multiples
| P/E Ratio | -14.17 |
| Price / Book | 4.54 |
| P/S | 6.21 |
| EV/EBITDA | -11.93 |
| EV/Sales | 5.42 |
| EV/FCF | -18.07 |
| P/FCF | -20.69 |
| Earnings Yield | -6.82% |
| FCF Yield | -4.83% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 56.47% |
| EBIT Margin | -49.72% |
| EBITDA Margin | -45.43% |
| Operating Margin | -58.73% |
| Net Margin | -41.86% |
| Return on Equity | -27.40% |
| Return on Assets | -17.49% |
| Return on Invested Capital | -29.28% |
| Return on Capital Employed | -40.83% |
Financial Health
| Current Ratio | 2.13 |
| Quick Ratio | 1.92 |
| Cash Ratio | 1.42 |
| Debt / Equity | 0.42 |
| Debt / Assets | 23.69% |
| Net Debt / EBITDA | 1.73 |
| Interest Coverage | -44.13 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -0.22 |
Per-Share Data
| Revenue per share | 4.02 |
| Book Value per share | 5.43 |
| Cash per share | 5.53 |
| FCF per share | -1.21 |
| Tangible Book Value per share | 4.64 |
| Dividend per share | 0.00 |
Related companies: AAPG · APGE · CDTX · CNTA · IDYA · IRON · LEGN
Explore sector: Healthcare · Biotechnology
More sections of ZLAB: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks